CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Ascentage Pharma Publishes Presentation on APG-5918 T-Cell Lymphoma Study

By Public Technologies
  • Ascentage Pharma published an announcement outlining clinical and preclinical data selected for the ASH annual meeting, December 12-15, 2026.
  • APG-5918's first clinical data will receive an oral presentation, showing a 44.7% objective response rate among 47 evaluable relapsed/refractory T-cell lymphoma patients.
  • At 600 mg daily, APG-5918 achieved a 65% objective response rate among 20 evaluable patients; disease control reached 95%.
  • No dose-limiting toxicities occurred during dose escalation, supporting 600 mg daily as the recommended Phase 2 dose.
  • Olverembatinib combined with lisaftoclax achieved complete remission in nine of 10 evaluable pediatric patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261105-12400926), on November 04, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk